PEARL: Pathway Exploration and Analysis in Renal Lupus

PEARL：肾狼疮的通路探索与分析

• 批准号: 10075543
• 负责人: Betty Diamond
• 金额: $ 106.36万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-24 至 2022-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10075543
• 关键词: Adverse effects; Bioinformatics; Biological; Biopsy Specimen; Blood; Blood specimen; Cells; Cessation of life; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Consent; Data; Disease; Disease model; End stage renal failure; Enrollment; Ensure; Event; Exhibits; Expression Profiling; Flare; Funding; Gene Expression; Gene Expression Profile; Gene Expression Profiling; Generations; Genetic Transcription; Goals; Hematopoietic; Histologic; Immune; Immunophenotyping; Immunosuppression; Individual; Infertility; Inflammation; Inflammatory; Inflammatory Infiltrate; Inflammatory Response; Infrastructure; Intervention; Kidney; Lead; Longitudinal Studies; Lupus; Lupus Nephritis; Malignant Neoplasms; Measures; Medical; Methods; Molecular; Molecular Profiling; Nephritis; Opportunistic Infections; Osteoporosis; Outcome; Pathogenesis; Pathogenicity; Pathology; Pathway interactions; Patients; Pattern; Phase; Phenotype; Pilot Projects; Prediction of Response to Therapy; Protocols documentation; RNA; Regimen; Renal Tissue; Research Design; Research Personnel; Resolution; Resources; Risk; Sampling; Site; Surrogate Markers; Systemic Lupus Erythematosus; Techniques; Technology; Therapeutic; Time; Tissues; Toxic effect; Tumor-infiltrating immune cells; Urine; clinical decision-making; conventional therapy; design; experience; gene function; improved; insight; interest; interstitial; kidney biopsy; nephritis therapy; new technology; new therapeutic target; novel; pathogen; patient stratification; phase 1 study; phase 2 study; predicting response; public health relevance; response; rheumatologist; single-cell RNA sequencing; therapeutic target; tissue injury; tissue repair; transcriptome sequencing; treatment response

 DESCRIPTION (provided by applicant): Nephritis is a common and serious manifestation of Systemic Lupus Erythematosus for which there is no adequate therapy. Some patients will exhibit a response to current immunosuppressive regimens while others will not; all are at risk for on and off target toxicities. The current proposal is to apply new technologies for high resolution analyses of gene expression and immunophenotype to kidney, blood and urine of lupus patients with active nephritis in order to develop a better understanding of disease pathogenesis and tissue injury, and stratify patients with respect to therapeutic response for more informed clinical decision making. We will explore blood and urine for less invasive surrogate markers for kidney inflammation. Our plan relies of optimization of analytic approaches, informed choice of cellular subpopulations to analyze, followed by two small studies to refine and validate the approach. In the first, we will study kidneys, blood and urine o 20 patients at a time of renal flare in order to dissect patterns of inflammation. In the second we will study cellular subsets in blood of 40 patients who were part of a clinical trial of lupus nephritis to understand changes from baseline profiles of gene expression and function response in those who experienced a full clinical response to therapy and those who failed to respond. Finally, we will use the information from these studies to design a large scale longitudinal study of patients with lupus nephritis. This unbiased re-examination of this unmet medical challenge should identify novel therapeutic targets, inform the generation of new models of disease, and lead to predictors of response that can then be validated in clinical trials We have unique technology resources and a powerful consortium of clinical investigators in the newly established Lupus Nephritis Trials Network that includes: (i) the infrastructure and expertise for clinical study implementation; (ii) protocols and consents for acquisition of blood, urine, and biopsy specimens; and (3) scalability to move from phase 0 and 1 to phase 2 at the appropriate time.